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A Case Report of an Aggressive Mantle Cell Lymphoma Masquerading as a
Chronic Lymphocytic Leukemia With Catastrophic Treatment Complications
Ranjit Nair, MD, Shereen Gheith, MD, PhD, Nicholas Lamparella, DO
Lehigh Valley Health Network, Allentown, Pennsylvania

Case Presentation:

Discussion:

Mantle cell Lymphoma (MCL) and chronic lymphocytic leukemia (CLL) account for majority of Small B-cell
neoplasms (SBCNs) that express CD5 without CD10. We present a patient case with aggressive MCL presenting
with leukocytosis and splenomegaly mimicking CLL initially on immunophenotypic features.
A 55-year-old presented with abdominal pain, drenching night sweats, early satiety, anorexia and significant
weight loss for 8-month duration. On exam she had generalized lymphadenopathy and massive splenomegaly.
Complete blood cell count showed pancytopenia with normal blood chemistry and LDH 778 U/L (Table1).
Differential count showed predominant lymphocytosis. Peripheral smear
Table 1
showed increased lymphocytes, condensed nuclear chromatin, smudge
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cells and occasional left shifted neutrophils. CT imaging showed diffuse
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and CD11c (Figure 2). The findings were most compatible with a diagnosis of LDH
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chronic lymphocytic leukemia. FISH panel was pending at this point.
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Due to B-symptoms and ongoing pain, decision was made to initiate FCR
chemotherapy (Fludarabine, Cyclophosphamide, Rituximab). A bone marrow
was done and rituximab treatment was initiated a day later. Thirty minutes
post-initiation of Rituximab, patient developed rigors, chills and nausea.
She became hypotensive, hypoglycemic and developed respiratory failure
requiring intubation and vasopressor support. Her clinical features and work
up (Table 1) were consistent with Cytokine Release Syndrome (CRS) and she
was started on steroids.
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She was treated with antibiotics, aggressive fluid resuscitation, bicarbonate infusion and emergently initiated
on hemodialysis. Echocardiogram showed dilated right ventricle with decreased Ejection fraction and CT scan
showed findings concerning for splenic infarction.
By this time the peripheral blood FISH panel resulted with t(11;14) consistent with MCL. Bone marrow biopsy
resulted as very aggressive MCL with associated TP53 deletion and Ki-67 proliferation index 60% (Figure 3).
Though her clinical status improved, she developed decreased vision in both eyes. On day 30, she developed
intractable abdominal pain and severe thrombocytopenia. Urgent CT scan demonstrated splenic rupture and
hemoperitoneum (Figure 4). She was made comfort care and died shortly after.
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Figure 1: CT scan
image showing massive
splenomegaly.
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Figure 2: Flow cytometry showing a
large monoclonal B-cell population Kappa
light chain restriction, dim CD19, CD20,
CD5, and variable expression of CD23.
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Figure 3A: Bone marrow core biopsy (40x magnification)
(insert in white box 100x magnification) showing sheets
of large transformed lymphocytes with occasional nucleoli
prominent nucleoli.
Figure 3B: Bone marrow aspirate (100x magnification)
showing large lymphoid cells with slightly folded nuclei and
vasicular chromatin.

MCL is an aggressive non-Hodgkins lymphoma with poorer prognosis of all other lymphomas. Though not curable
outside of transplant, frequent remissions (60%-90%) can be obtained albeit short lasting (1-2 years).1 MCL is
often misdiagnosed as CLL. Flow cytometric immunophenotyping often helps differentiate CLL from MCL, and
a characteristic CLL phenotype is considered essentially diagnostic.2 There is significantly higher expression
of CD23 in CLL. MCL typically is negative for CD23, but 25 % cases can be dim positive.3,4 CLL on the other
hand can occasionally be CD23 negative. Thus NHL often can be less obvious and confounds the diagnosis if a
leukemic phase occurs at presentation. MCL is more specifically identified by the presence of the translocation
t(11;14)(q13;q32), but cyclin D1-negative variants do exist. FISH assay is by far the most sensitive and specific
technique for t(11:14) identification.5 This should be considered in newly diagnosed CLL patients with atypical
features especially B grade symptoms at initial presentation, massive splenomegaly, immunopenotypic feature
showing moderate bright CD20 and bright surface light chain expression. Given the importance of stem cell
transplants for MCL patients, it is important to recognize this, as fludarabine therapy can impair successful
collection of stem cells.6 Bone marrow biopsy though not required for diagnosis for CLL, but should be considered
in atypical presentations, discordance in the immunophenotypic markers, presence of cytopenias and preferably
prior to treatment initiation.
Rituximab induced CRS or splenic rupture is very rarely reported in literature. There is emerging evidence which
implicates IL-6 as a central mediator in CRS. Toclilizumab (IL-6 blocker) is used as first line immunosuppressive
therapy in clinical trials.7 Ophthalmic side effect of rituximab is reported including transient ocular edema,
transient visual changes and severe loss of visual acuity; however these are very rare. The risk of reaction may
correlate with the aggressiveness and burden of the disease. Hence we should consider aggressive hydration,
pre-treatment with steroids, antihistamines and holding or dose reduction of rituximab with first cycle. Postmarketing surveillance database on rituximab indicates a mortality of 0.04–0.07% associated with the drug,
however due to it increasing use, there should be high index of suspicion for these side effects as they are life
threatening.
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Figure 4: CT scan image
showing splenic rupture.

